CSL Behring to Close California R&D Site Amid Shift in Gene Therapy Strategy

Closure Date:
CSL Behring will close its Pasadena, California R&D site by the end of January 2025[1][2].

Reason for Closure:
The closure is part of a strategic pivot away from ex vivo gene therapy and towards more efficient operations[4][5].

Relocation:
The company will move its cell and gene therapy R&D activities to Waltham, Massachusetts[1][3].

Industry Context:
The move reflects broader trends in the biotech industry focusing on strategic growth and efficiency[5].

Existing Gene Therapy:
CSL's sole marketed gene therapy, Hemgenix (etranacogene dezaparvovec-drlb), continues to be a focus for the company[4].